- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 102
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
- Interventions
- Metformin, Placebos
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Schizophrenia, Schizoaffective Disorders
- Interventions
- olanzapine, amantadine, metformin, zonisamide, Wellness education
- Drug · Behavioral
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 5
- States / cities
- National City, California • Canton, Ohio • Johnson City, Tennessee + 2 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Low Metformin, Mid Metformin, High Metformin, Metformin
- Drug
- Lead sponsor
- NuSirt Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
- Conditions
- Impaired Glucose Tolerance
- Interventions
- Exenatide, Metformin
- Drug
- Lead sponsor
- St. Paul Heart Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Saint Louis Park, Minnesota • Saint Paul, Minnesota
- Conditions
- Overweight, Autism Spectrum Disorder
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- Holland Bloorview Kids Rehabilitation Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Melanoma
- Interventions
- Dabrafenib, Trametinib, Metformin
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky
- Conditions
- Prostate Carcinoma
- Interventions
- Metformin, Simvastatin
- Drug
- Lead sponsor
- Nicholas Mitsiades
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Low Metformin, Metformin, Mid Metformin, High Metformin
- Drug
- Lead sponsor
- NuSirt Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
- Drug · Behavioral · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Gestational Diabetes
- Interventions
- Glyburide, Glucovance
- Drug
- Lead sponsor
- Texas Tech University Health Sciences Center, El Paso
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Advanced Melanoma
- Interventions
- Pembrolizumab Injection [Keytruda], Metformin
- Drug
- Lead sponsor
- Yana Najjar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Drug Interactions
- Interventions
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Prostate Cancer
- Interventions
- Placebo, Metformin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Gestational Diabetes
- Interventions
- metformin, Glyburide
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 13 Years and older · Female only
- Enrollment
- 149 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2023
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Healthy Subjects
- Interventions
- Metformin 500 mg Oral Tablet, Levoketoconazole 150 - 600 mg (BID)
- Drug
- Lead sponsor
- Cortendo AB
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Type 1 Diabetes
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 18 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Vildagliptin, metformin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 914 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Covid19
- Interventions
- Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
- Drug · Other
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 10,956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 110
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
- Drug · Behavioral
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 60
- States / cities
- Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
- Interventions
- Metformin XR plus placebo, Metformin XR plus liraglutide
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Diabetes
- Interventions
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
- Interventions
- L-NMMA
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Houston, Texas